DPP4 Inhibitors: a new approach in diabetes treatment
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2008/07/01
-
Journal
-
Indian UGC (journal)
-
Refrences74
-
Citations64
-
John Doupis
-
Aristidis Veves
Cite
Doupis, John, and Aristidis Veves. “DPP4 Inhibitors: A New Approach in Diabetes Treatment”. Advances in Therapy, vol. 25, no. 7, 2008, pp. 627-43, https://doi.org/10.1007/s12325-008-0076-1.
Doupis, J., & Veves, A. (2008). DPP4 Inhibitors: a new approach in diabetes treatment. Advances in Therapy, 25(7), 627-643. https://doi.org/10.1007/s12325-008-0076-1
Doupis J, Veves A. DPP4 Inhibitors: a new approach in diabetes treatment. Advances in Therapy. 2008;25(7):627-43.
Journal Categories
Medicine
Medicine (General)
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims data
- The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence oSf erectile dysfunction and related health concerns in the general population
- Screening Depressed Patients in Family Practice
- The Medical Risks of Obesity
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients | The Journal of Clinical Endocrinology & Metabolism |
| 174 | 2007 |
| Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes | Diabetes Research and Clinical Practice |
| 228 | 2007 |
| The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin | European Journal of Clinical Pharmacology |
| 52 | 2007 |
| Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes | International Journal of Clinical Practice |
| 178 | 2007 |
| Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes | Diabetologia |
| 270 | 2007 |
Refrences Analysis
The category
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the endocrine glands. Clinical endocrinology 65
is the most frequently represented among the references in this article. It primarily includes studies from Diabetologia and Diabetes Care. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Citations Analysis
The category
Medicine: Therapeutics. Pharmacology 25
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Ecological Therapy for Cancer: Defining Tumors Using an Ecosystem Paradigm Suggests New Opportunities for Novel Cancer Treatments and was published in 2008. The most recent citation comes from a 2024 study titled Therapeutic effects of anti-diabetic drugs on traumatic brain injury. This article reached its peak citation in 2023, with 7 citations. It has been cited in 55 different journals, 20% of which are open access. Among related journals, the Advances in Therapy cited this research the most, with 3 citations. The chart below illustrates the annual citation trends for this article.